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DOI 10.1016/j.ccr.2011.01.019SUMMARYAbrogation of negative feedback control represents a fundamental requirement for aberrantly activated
signaling pathways to promote malignant transformation and resistance to therapy. Here we identify URI,
which encodes a mitochondrial inhibitor of PP1g and PP1g-mediated feedback inhibition of S6K1-BAD
survival signaling, as an oncogene amplified and overexpressed in ovarian cancer cell lines and human
ovarian carcinomas. URI is an ‘‘addicting’’ oncogene selectively required for the survival of ovarian cancer
cells with increased URI copy number. By constitutively detaining PP1g in inactive complexes, URI sustains
S6K1 survival signaling under growth factor–limiting conditions and mediates resistance of cells to cisplatin.
Thus, oncogenic activation of URI defines an important mechanism for activating mitochondrial S6K1-BAD
signaling and promoting cell survival through disabling PP1g-dependent negative feedback inhibition.INTRODUCTION
Tumorigenesis is a multistep process, in which mutations in key
cellular genes produce a series of acquired capabilities that
allow the developing cancer cell to survive many stresses,
including limitations of oxygen, glucose, growth factors, and
nutrients (Johnstone et al., 2002). Because many of these
stresses activate the intrinsic apoptotic pathway at mitochon-
dria, the ability of cancer cells to evade this death pathway has
become an established hallmark of cancer (Hanahan and Wein-
berg, 2000). The fact that this mitochondrial apoptotic pathway
operates under conditions of physiological and drug-induced
cell death explains also why the very genetic alterations thatSignificance
Augmentation of signaling output and elicitation of cancer phe
gation of negative feedback mechanisms by oncogenic even
Such oncogenic events and the signaling pathways they affec
with reduced nonspecific drug-associated toxicity. We descri
whose gene product abrogates negative feedback on S6K1 su
of this feedback renders URI-amplified ovarian cancer cells a
have implications for the development of mechanism-based th
tumors are characterized by URI amplification.mediate intrinsic resistance to physiologic death stimuli also
lead to inherent resistance of cancer cells to numerous chemo-
therapeutic drugs (Johnstone et al., 2002).
Genetic alterations affecting life-death decisions at mitochon-
dria often deregulate intracellular signaling pathways that
transduce survival signals. Prominent among these are the phos-
phatidylinositol 3-kinase (PI3K)–Akt/PKB and the mammalian
target of rapamycin (mTOR)–S6K1 pathways that modulate the
activity of members of the Bcl-2 family of pro- and antiapoptotic
proteins (Bergmann, 2002). Both Akt/PKB and S6K1 have been
shown to phosphorylate, as part of their prosurvival functions,
the proapoptotic BH3-only protein BAD at distinct sites, which
in turn sequesters BAD in the cytoplasm, thereby preventingnotypes by activated signaling pathways depends on abro-
ts that directly target components of the feedback system.
t are expected to constitute targets for ‘‘targeted’’ therapies
be here the discovery of an ovarian cancer oncogene, URI,
rvival signaling, thereby enhancing cell survival. Abrogation
lso resistant to cisplatin-induced apoptosis. These findings
erapies targeting the URI cancer pathway in patients whose
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Figure 1. URI Amplification Correlates with Aggressive Behavior in Ovarian Cancer
(A) Ovarian cancers analyzed by fluorescence in situ hybridization (FISH) analysis with green and red probes detecting URI and the chromosome 19 centromer,
respectively, and by immunohistochemistry (IHC) for URI protein using TMAs. Diploid human ovarian surface epithelium (HOSE) and carcinomas (Ca) with normal
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Cancer Cell
URI Functions as an Oncogeneassociation of BAD with Bcl-2 or Bcl-XL proteins (Bergmann,
2002; Datta et al., 2002; Harada et al., 2001). This mechanism
enhances resistance of cells to undergo apoptosis in response
to death cues (Bergmann, 2002; Datta et al., 2002; Harada
et al., 2001). It also links growth factor and nutrient signals
integrated via the PI3K-Akt/PKB and mTOR-S6K1 pathways to
the regulation of cell survival. Counterbalancing the activity of
survival kinase-mediated phosphorylation of BAD are phos-
phatases, including mitochondria-associated phosphatase 1
gamma (PP1g) (Danial et al., 2003; Djouder et al., 2007; Klumpp
and Krieglstein, 2002). It has been demonstrated that the ability
of PP1g to function as a phosphatase counterbalancing S6K1-
BAD survival signaling depends, in part, on the phosphorylation
status of its interaction partner URI, a member of the prefoldin
family of molecular chaperones (Gstaiger et al., 2003; Siegert
et al., 2000). In its un(der)phosphorylated form, URI is bound to
PP1g and functions as its inhibitor. Dissociation of PP1g from
bound URI is initiated by S6K1-mediated phosphorylation of
URI at Ser-371, which when liberated, proceeds to dephosphor-
ylate S6K1 and possibly BAD (Djouder et al., 2007). On the basis
of these findings, a model has been proposed in which acute
activation of S6K1 in response to growth factor and nutritional
cues triggers a negative feedback system operating at mito-
chondria that involves the phosphorylation of URI and the subse-
quent liberation of PP1g, which dampens S6K1 survival
signaling. Under growth factor and nutrient-rich conditions, this
negative feedback system operates at basal/low levels.
On the basis of the above-noted model, it follows that during
tumor evolution, genetic alterations abrogating the normal oper-
ation of this negative feedback system could result in enhanced
signaling output (i.e., increased S6K1 cell survival) and conse-
quently increased resistance of cells to apoptosis in response
to stress cues. In this context, the chromosomal locus 19q12
whereURI resideswas found amplified in a variety of carcinomas
(Leung et al., 2006; Lin et al., 2000; Nakanishi et al., 2000;
Schraml et al., 2003; Snijders et al., 2003). Moreover, the
19q12 amplicon has been shown in a genomewide screen to
correlate with resistance against platinum-based chemotherapy
in ovarian cancer (Etemadmoghadam et al., 2009). Despite
attempts to improve therapeutic options for this cancer type,
malignancies derived form the normal surface epithelium have
still the worst prognosis among gynecological tumors and since
decades, standard treatment consists of platinum-based
chemotherapy after surgery.
Given these observations, we tested in this study the hypoth-
esis that oncogenic activation of URI occurs in a subset of(weak) URI expression and high-copy amplified carcinomas with overexpression
higher magnification highlight expression levels within one cell using adjusted co
(B and C) URI amplification and URI protein expression.
(D and E) Correlation between URI amplification and protein expression. Bars re
(F) Fold changemRNA expression normalized to human primary HOSE by quantita
cases.
(G) Correlation of URI protein expression/amplification with clinicopathological p
stratified into three groups: (i) weak protein expression/URI not amplified, (ii) stro
(H) Corresponding Kaplan-Meier survival analysis (p = Log rank).
(I and J) URI FISH and IHC of normal epithelium and adenocarcinomas of the sto
represent 5 mm (FISH) and 10 mm (IHC). Differences in number of cases among im
inadequate tumor tissue), a problem associated with TMAs.
See also Figure S1.ovarian cancers and contributes in this setting to increased
ovarian cancer cell survival by disabling negative feedback
control on S6K1 signaling. We also investigated whether the
gene product of URI might contribute to resistance of ovarian
cancer cells to cisplatin and rapamycin.
RESULTS
URI Amplification Correlate with Aggressive
Behavior in Ovarian Cancer
A number of studies reported copy number gain or amplification
of 19q12 in ovarian cancer (Etemadmoghadam et al., 2009;
Hu et al., 2003; Lin et al., 2000; Schraml et al., 2003). Because
the URI locus resides within this amplified region, we analyzed
URI gene copy alterations by fluorescence in situ hybridization
(FISH) and protein expression by immunohistochemical staining
(IHC) of human ovarian cancer specimens derived from two
different cohorts (Figure 1; see Figure S1A available online).
URI amplification, as defined by the presence of at least six
gene copies per nucleus, was detectable in 10% of ovarian
carcinomas, with no preference for histological subtype (Figures
1A and 1B; Figure S1B). The majority of cases (36 of 41 ovarian
tumors) harbored more than 10 copies of the URI locus per
nucleus (data not shown). URI amplification was detectable in
neither normal human ovarian surface epithelium (HOSE) (Fig-
ure 1A) nor other types of ovarian malignancies, such as nonin-
vasive borderline or ovarian germ cell tumors (data not shown).
Next we determined whether ovarian carcinomas are charac-
terized by increased URI protein levels. URI expression was
assessed by IHC of human ovarian cancer specimens on tissue
microarrays, and the average of the individual scores of a two-
tiered scoring system (weak versus strong) evaluated by three
different pathologists was used for subsequent analysis. As
shown in Figure S1C, the interobserver variability was low. The
URI antibody used in this study specifically detects endogenous
URI on paraffin-embedded sections (Figure S1D). In almost 40%
of cases, we detected high levels of URI (Figure 1C), compared
to HOSE, where expression of URI was defined as weak (Fig-
ure 1A). By complementing this data set with URI gene copy
alterations, we found that all ovarian cancers with URI amplifica-
tion consistently displayed URI overexpression and that a subset
of ovarian cancers without URI amplification still expressed high
levels of URI (Figures 1D and 1E). These results imply that URI
gene copy alterations represent one mechanism of deregulation
of URI protein expression. Consistent with this notion, we
observed the highest levels of URI mRNA and protein levels in(strong) are shown. Bars represent 5 mm (FISH) and 12 mm (IHC). Inlays with
ntrast/brightness settings for each individual cell (see also below).
present 5 mm (FISH) and 12 mm (IHC).
tive RT-PCR and corresponding protein expression bywestern blot of selected
arameters (R = correlation coefficient; p = Kendall beta-tau). Expression was
ng expression/not amplified, and (iii) strong expression/URI amplified.
mach, endometrium, breast, and small-cell lung cancer (SCLC) on TMA. Bars
munohistochemical markers were due to tissue damage (either tissue loss or
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URI Functions as an Oncogenethose ovarian cancers characterized by URI gene copy alter-
ations (Figure 1F).
To assess whether URI amplification and/or overexpression is
associated with clinicopathological parameters of tumor aggres-
siveness, we subdivided ovarian carcinomas into three groups
according to URI amplification/protein expression patterns: (1)
weak expression and not amplified, (2) strong expression and
not amplified, and (3) strong expression and amplified. Impor-
tantly, the latter group was characterized by higher histological
grade, broader tumor spread (pT), and failure to respond to plat-
inum-basedchemotherapy (Figure 1G). In contrast, themoderate
URI protein expression seen in the absence of URI amplification
was linked to broader tumor spread but not to grade or chemo-
therapy response (Figure 1G), implying that either the higher
protein expression of URI in the context of amplification or other
coamplified genes at 19q12 may contribute to a more malignant
phenotype. We did not observe significant correlations with
lymphatic (pN) or distant metastatic spread (cM) in any of the
above-noted three groups (Figure 1G).
URI amplification and protein expression correlated signifi-
cantly with poor disease-specific patient’s survival (Figure 1H).
Similar observations were obtained when the two different
ovarian cancer cohorts were analyzed separately or when the
pooled cohorts were evaluated by three different observers
(Figures S1E and S1F). The quality of survival data sets used in
this study are illustrated by Kaplan-Meier curves of established
prognostic factors including tumor spread (pT) and chemo-
therapy response (Figure S1G).
Amplification at 19q12 has been described in other carcinoma
entities (Leung et al., 2006; Lin et al., 2000; Schraml et al., 2003;
Snijders et al., 2003). Interestingly, we found a substantial
number of cancers characterized by URI amplification and
overexpression, including adenocarcinomas of the stomach,
endometrium, breast (with medullary histology), and small-cell
lung cancer (SCLC) (Figures 1I and 1J). Thus, URI is amplified
and overexpressed in a substantial fraction of several distinct
cancer types.
Consequences of Suppression of URI Function
in Ovarian Cancer Cells
Many oncogenes, when overexpressed, render cancer cells
dependent on the continued function of the oncogene for cell
proliferation or survival. Because the above-noted data imply
that URI may function as an oncogene, we tested whetherFigure 2. Consequences of Suppression of URI Function in Ovarian Ca
(A) Immunohistochemical, FISH, quantitative RT-PCR, and immunoblot analysis o
tion (OVCAR-3, FU-OV-1). Bars represent 15 mm (IHC) and 5 mm (FISH).
(B) Clonogenic assay and quantification of ovarian cell lines after URI knockdown
dation) (see Figure S2A) of three independent experiments in triplicate (*p < 0.05
(C) TUNEL staining with quantification and analysis of anaphases after URI depl
Student’s t test). Bars represent 15 mm.
(D) Number of tumors grown subcutaneously in nude mice after injection of TOV
(E) Tumor size increase over time of control and URI knockdown TOV-21G cells
(F) Immunoblotting of whole cell extracts derived from two different clones of OVC
indicated proteins.
(G) Tumor growth of two different clones of OVCAR-3(tURI) or OVCAR-3(tCon) in
5 days after injection of the indicated cells. Xenograft experiments represent 6mic
OVCAR-3(tCon). Time point 0 indicates the start of the volume measurements.
All error bars in the entire figure represent ± SD. See also Figure S2.ovarian cancer cells are functionally dependent on URI. To this
end, we selected a panel of five cell lines of ovarian origin that
reflected best the different URI levels encountered in human
tissue. Immortalized HOSE cells express low levels of URI
mRNAs and protein (Figure 2A). Human ovarian surface carci-
noma TOV-21G and SKOV-3 cells, which do not display URI
gene copy alterations, express low to moderate levels of URI
mRNAs and protein, whereas human ovarian surface carcinoma
OVCAR-3 and FU-OV-1 cells are both characterized by URI
amplification and high levels of URI mRNA and protein expres-
sion (Figure 2A).
Using two different short-hairpin RNAs (shRNAs) targeting URI
mRNAs, we assessed the effects of URI depletion on colony
formation of these different ovarian cell lines. Immunoblotting
confirmed that URI depletion was very efficient (Figure S2A).
Strikingly, URI depletion selectively reduced colony formation
of OVCAR-3 and FU-OV-1 cells (Figure 2B). This effect was
considerably less pronounced or absent in SKOV-3 or TOV-
21G cells, respectively (Figure 2B). Consistent with this finding,
URI knockdown caused significant cell death of OVCAR-3 and
FU-OV-1 cells but not of SKOV-3, TOV-21G, or HOSE cells, as
evidenced by TUNEL staining (Figure 2C). In accordance with
this finding, the number of detectable anaphase cells, assessed
in parallel as an indicator of active proliferation, was selectively
reduced in URI-depleted OVCAR-3 and FU-OV-1 cells (Fig-
ure 2C). In addition, URI depletion caused also cell death in
cancer cell lines of nonovarian origin that are characterized by
URI amplification including MKN-7 (gastric cancer), Lu-143
(SCLC), EFE-184 (endometrial cancer), and MDA-MB-157
(medullary breast cancer) (Figures S2B and S2C). Finally, URI
knockdown in URI-amplified OVCAR-3 cells abolished their
ability to form tumors in immunodeficient mice (Figure 2D). In
contrast, there was no negative effect on tumor growth or on
the kinetics of tumor growth when URI was depleted from
TOV-21G cells (Figure 2E). In each case, URI depletion was
effective, as evidenced by immunoblotting analysis (data not
shown).
To assess a potential requirement of URI for tumor growth
after tumor establishment, we established OVCAR-3 cell lines
expressing tetracycline (tet)–regulable (tet-off) microRNA-based
hairpins (Dickins et al., 2005) targeting URImRNAs, referred to as
OVCAR-3(tURI), or a ‘‘scrambled’’ control shRNA, referred to as
OVCAR-3(tCon). In the presence of doxycycline, OVCAR-3
(tCon) and OVCAR-3(tURI) cell lines expressed similar levels ofncer Cells
f ovarian cell lines without (HOSE, TOV-21G, SKOV-3) and with URI amplifica-
with two different short hairpin RNAs (KD1, KD2; immunoblot knockdown vali-
and **p < 0.01, Student’s t test).
etion of three independent experiments in triplicate (*p < 0.05 and **p < 0.01,
-21G or OVCAR-3 cells (**< 0.01, Student’s t test).
in xenograft experiments using 6 mice per group.
AR-3(tURI) or OVCAR-3(tCon) cells in the presence or absence of doxycyline for
a xenograft mouse model. Doxycycline was removed from the drinking water
e for OVCAR-3(tURI) (Clone 1) and 7mice for eachOVCAR-3(tURI) (Clone 2) and
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Figure 3. Requirements of 19q12 Coamplified Genes for Cell Survival of Ovarian Cancer Cells
(A) Quantitative SNP array analysis of the 19q12 amplicon of FU-OV-1 and OVCAR-3 cells. All known coding genes within this region are highlighted by
different colors.
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URI Functions as an OncogeneURI. However, removal of doxycycline induced efficient reduc-
tion of URI selectively in the OVCAR-3(tURI) cell lines (Figure 2F).
Consistent with this result, the ability of OVCAR-3(tURI) cell lines
to form colonies alsowas substantially reduced in the absence of
doxycycline (Figure S2D). Given these cell-culture data, we next
injected OVCAR-3(tCon) and OVCAR-3(tURI) cell lines subcuta-
neously into the flanks of nude mice treated with doxycycline.
Importantly, removal of doxycycline after limited tumor growth
in vivo reduced further tumor progression of the OVCAR-3
(tURI) xenografts but not of the OVCAR-3(tCon) xenografts (Fig-
ure 2G). These results suggest that URI function is required both
for de novo tumorigenesis and for further tumor progression after
tumor establishment.
Requirements of 19q12 Coamplified Genes
for Cell Survival of Ovarian Cancer Cells
Next we asked whether these ovarian cancer cells are similarly
dependent for their survival on other genes coamplified at
19q12. SNP array analysis of FU-OV-1 and OVCAR-3 cells re-
vealed a circumscribed amplicon at 19q12 encompassing seven
genes (in FU-OV-1 cells) and six genes (in OVCAR-3 cells) (Fig-
ure 3A). In both cell lines, URI located precisely at the last peak
of the amplicon, in FU-OV-1 cells even being the most amplified
gene in the entire genome (data not shown). In fact, a compara-
tive analysis of gene amplification at 19q12 between 116 human
ovarian carcinomas (Etemadmoghadam et al., 2009) and
FU-OV-1 and OVCAR-3 cells revealed a similar pattern of coam-
plified genes (Figures S3A and S3B).
All genes present in the amplicon were up-regulated in ovarian
cancer cells harboring an amplification, except VSTM2B, encod-
ing V-set and a transmembrane domain containing 2B, which
was expressed at very low levels in all cell lines tested (Figure 3B).
To assess the functional significance of these genes with respect
to cell survival in the context of 19q12 amplification, we per-
formed clonogenic assays in nonamplified (HOSE, TOV-21G)
and amplified (OVCAR-3, FU-OV-1) ovarian cells by depleting
individually the mRNAs derived from all coding genes at 19q12
(except for VSTM2B) using two different shRNAs (Figure 3C).
Strikingly, depletion of POP4, encoding processing of precursor
4, PLEKHF1, encoding pleckstrin homology domain containing,
family F (with FYVE domain) member, C19orf12, encoding
chromosome 19 open reading frame 12, and CCNE1, encoding
cyclin E, drastically reduced colony count in all cell lines
analyzed, indicating that within the core of the amplicon, four
genes were found to be essential for cell proliferation indepen-
dent of 19q12 amplification status (Figure 3D). Depletion of
UQCRFS1, encoding ubiquinol-cytochrome C reductase Rieske
iron-sulfur polypeptide, enhanced colony formation in all cell
lines except of TOV-21G (Figure 3D). This analysis indicates
that URI is the only coding gene within the amplicon 19q12
whose depletion selectively affects colony formation of cells
with a 19q12-amplification.(B) mRNA expression by quantitative RT-PCR (qPCR) of amplified genes in cell li
lines, brain represents positive control).
(C) Characterization of knockdown efficiency in FU-OV-1 cells with two different
(D) Clonogenic assay and quantification of indicated cell lines after knockdown of
in triplicate.
All error bars represent ± SD in the entire figure. See also Figure S3.URI Sustains Survival of URI-Amplified Ovarian Cancer
Cells Through a PP1g-Dependent Mechanism
Recently we reported that URI binds to and inhibits PP1g, an
interaction dynamically regulated by S6K1-mediated phosphor-
ylation of URI at Ser-371 (Djouder et al., 2007). Because URI is
highly overexpressed in ovarian cancer cells, in particular in
those with a 19q12 amplicon, and is required in these cells for
cell survival, we asked whether part of its potential oncogenic
function derives from its capacity to maintain PP1g constitutively
bound to it. Consequently, PP1gwould be inhibited and its proa-
poptotic function abolished. As shown in Figure 4A, the amount
of URI coimmunoprecipitating with PP1g from different ovarian
cell lines correlated with the degree of URI overexpression
(Figures 2A and 4A). We note that unlike URI, PP1g expression
does not vary significantly in these cell lines (Figure 4A). Similar
results were obtained in human tissues, where the highest
amount of URI-PP1g complexes was detected in those carci-
nomas with URI amplification (Figure S4A). Phosphorylation of
URI at Ser-371 is known to mediate disruption of URI-PP1g
complexes. Because ovarian cancer cell lines overproducing
URI are characterized by increased abundance of URI-PP1g
complexes, onemight predict that in these cells phosphorylation
of URI at Ser-371 is low. Indeed, we observed little variation in
Ser-371 phosphorylation of URI among the different cell lines
(Figure 4B), implying that up-regulation of URI protein and Ser-
371 phosphorylation is uncoupled.
According to the above-noted hypothesis, cell death induced
by URI depletion should be dependent on PP1g function. As
shown in Figure 4C, decreases in cell number and the number
of anaphases as well as the increase in apoptosis associated
with URI depletion in FU-OV-1 cells is rescued by concomitant
knockdown of PP1g. Immunoblotting revealed that S6K1 and
its downstream target BAD were dephosphorylated at Thr-389
and Ser- 136, respectively, in URI-depleted cells (Figure 4D).
Combined knockdown of URI and PP1g recovered the phos-
phorylation of both S6K1 and BAD at these sites. These results
are in line with the view that URI has properties of an oncoprotein
in ovarian cancer cells with a 19q12 amplicon and that it func-
tions, in part, by detaining PP1g inactive and disabling the nega-
tive feedback to limit S6K1 survival signaling.
To further corroborate this hypothesis, we tested next whether
overexpression of URI might promote resistance against
apoptosis in otherwise not-amplified TOV-21G cells that natu-
rally display low URI levels. To this end, we generated retrovirally
infected TOV-21G cell pools stably expressing HA-tagged URI
(wt) or URI(S371A) phosphosite mutant, which constitutively
entraps PP1g and thus is expected to closely mimic the potential
oncogenic properties of URI. Both HA-tagged URI species are
produced to similar levels in these pools, and the degree of over-
expression of theseHA-taggedURI species ismoderate (2–3 fold
over endogenousURI) (Figure S4C). Importantly, we found signif-
icantly more HA-URI(S371A) protein coimmunoprecipitating withnes as indicated. Silenced VSTM2B expression (cycle threshold >36 for all cell
short hairpin RNAs used against indicated genes by qPCR.
the genes identified to be amplified at 19q12 of three independent experiments
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URI Functions as an Oncogeneendogenous PP1g than with HA-URI(wt) (Figure 4E). In clono-
genic assays performed under various serum concentrations,
the HA-URI(S371A)–producing pool grew significantly more
colonies than the corresponding HA-URI(wt) –expressing pool
or the vector control pool under low serum concentrations
(Figure 4F). This difference was most evident at 5% or 2.5%
serum concentrations (Figure 4F), indicating that conditions
promoting constitutive URI-PP1g complex formation confer
a cell survival advantage. Consistentwith these results, the phos-
phorylation status of S6K1 andBAD remained high in HA-URI(wt)
or (S317A)–producing pools even under low serum concentra-
tions (Figure 4G) and we observed less apoptotic cells under
the same conditions (Figure 4H). Furthermore, in clonogenic
assays, we also observed that URI-amplified OVCAR-3 and
FU-OV-1 cells grew more efficiently under serum-limiting condi-
tions than any of the non-URI-amplified SKOV-3, TOV-21G, and
HOSE cells (Figure S4D). In agreement with the proposedmolec-
ular mechanism, inURI-amplified cells, phosphorylation of S6K1
was maintained under low serum concentrations, whereas in
non-URI-amplified cells, phosphorylation of S6K1 was dimin-
ished (Figure S4D). Finally, by injecting TOV-21G cell pools
expressing either HA-URI(wt) or HA-URI(S371A) into nude
mice, we demonstrate accelerated tumor growth of TOV-21G
cell pools producing the URI phosphosite mutant protein (Fig-
ure 4I). Collectively, these data suggest that URI acts as an
ovarian cancer oncogene by increasing the threshold at which
a cell initiates apoptosis in response to stressors such as low
growth factor concentrations through constitutively inhibiting
PP1g and thereby allowing deregulated S6K1 survival signaling.
URI-Amplification and Overexpression Promotes
Ovarian Cancer Cell Survival in an S6K1-Dependent
Manner
As shown above, depletion of URI in ovarian cancer cells
with URI amplification such as FU-OV-1 or OVCAR-3 causes
dephosphorylation of S6K1 and BAD at Thr-389 and Ser-136,
respectively. Similar effects on S6K1 phosphorylation were
observed in other URI amplified cancer cell lines of nonovarian
origin (Figure S5A). Depletion of URI in nonamplified ovarian cells
did not cause significant dephosphorylation of S6K1 or BAD at
the respective sites (Figure 5A). Nonamplified ovarian cancer
cells were also more resistant to apoptosis in response to URIFigure 4. URI-Amplifed Ovarian Cancer Cells Are Characterized by Inc
(A) Immunoprecipitation of equal amounts of PP1g from the indicated ovarian c
OVCAR-3 cells was directly processed for immunoblotting and served as migrat
(B) Immunoblotting for URI and phospho-URI S371 on indicated cell lines.
(C) Knockdown of URI, PP1g, and URI + PP1g in FU-OV-1 cells by siRNA, TUNE
experiments in triplicate (*p < 0.05 and **p < 0.01, Student’s t test). Bars represe
(D) Corresponding immunoblot analysis against the total proteins and phosphos
(E) PP1g-immunoprecipitation blotted for indicated proteins on cells with retrovira
TOV-21G cells. WCEs of TOV-21G cells were directly processed for immunoblot
(F) Clonogenic assay with different serum concentrations and quantification in TO
0.01, Student’s t test).
(G) Immunoblotting analysis against the total proteins and phosphosites as indic
(H) TUNEL of TOV-21G cells cultured under different serum concentrations of thr
test).
(I) Tumor growth of TOV-21G cells with retroviral-mediated overexpression of HA
per group (p value, Wilcoxon rank).
All error bars in the entire figure represent ± SD. See also Figure S4.depletion (data not shown). Importantly, S6K1 was essential for
efficient colony formation (Figure 5B) and cell survival (Figure 5C)
for both (non-URI-amplified) TOV-21G and (URI-amplified)
FU-OV-1 cells, consistent with a principal requirement for
S6K1 for cell proliferation.
To directly test whether negative feedback inhibition of the
S6K1-BAD survival axis is disabled in URI-amplified ovarian
cancer cells, we depleted URI alone or in combination with over-
expression of myc-tagged S6K1 in FU-OV-1 and scored for cell
death. As expected, depletion of URI in these cells induced
substantial cell death (Figure 5D). Importantly, cell death in this
case was partially rescued by overexpression of myc-S6K1 (Fig-
ure 5D), suggesting that cell death observed in URI-depleted
FU-OV-1 cells is caused, at least in part, by lower levels of
S6K1 survival signaling. We also observed some cell death
upon overexpression of myc-S6K1 (Figure 5D). This is likely
due to S6K1-driven disruption of URI-PP1g complexes, because
in these cells little URI coimmunoprecipitated with PP1g
compared to control (Figure 5E), indicating that release of
PP1g had occurred. In accordance with this interpretation,
myc-S6K1-overexpressing cells displayed reduced levels of
BAD phosphorylation at Ser-136. In addition, myc-S6K1 overex-
pression counterbalanced dephosphorylation of BAD at Ser-136
caused by URI depletion (Figure 5F).
Next we examined whether this functional relationship
between URI levels and phosphorylation status of S6K1
and BAD extend to human ovarian cancer tissue. Indeed, URI
amplification and protein expression correlated significantly
with the phosphorylation status of S6K1 and BAD in ovarian
carcinoma tissues (Figure 5G). Similar correlations were found
in other cancer types (Figure S5B). In fact, when analyzing
gastric adenocarcinoma (because early ovarian lesions are
extremely rare), we detected URI amplification already at the
stage of noninvasive carcinoma in situ (5 of 5 cases). In this
context, amplification and URI overexpression in glands of
gastric carcinoma in situ matched with an increase in S6K1
phosphorylation and proliferation, whereas PP1g expression
did not change between normal glands and carcinoma in situ
(Figure S5C). Combined, these results support a potential role
for deregulated URI expression in promoting increased S6K1-
BAD survival signaling already at an early stage in at least
a subset of human cancers.reased Abundance of URI-PP1g Complexes
ell lines and immunoblotting for URI and PP1g. A whole cell extract (WCE) of
ion control for indicated proteins.
L staining, anaphases, and cell count with quantification of three independent
nt 15 mM.
ites as indicated.
l-mediated overexpression of HA-tagged wild-type URI and a S371Amutant in
ting and served as migration control for indicated proteins.
V-21G cells of three independent experiments in triplicate (*p < 0.05 and **p <
ated.
ee independent experiments in triplicate (*p < 0.05 and **p < 0.01, Student’s t
-tagged wild-type URI and a S371A mutant in nude mice over time of ten mice
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Figure 5. URI Maintains S6K1-Survival Signaling in Overexpressed Ovarian Cancer Cells
(A) Immunoblot analysis of HOSE, TOV-21G, SKOV-3, OVCAR-3, and FU-OV-1 ovarian cell lines after URI knockdown against the proteins and phosphosites
indicated.
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URI Functions as an OncogeneURI-Amplification and Overexpression Correlates
with Resistance of Ovarian Cancer Cells to Rapamycin
Our data suggest that URI amplification affects PI3K-mTOR
signaling in ovarian cancer cells downstream at the level of
S6K1. Therefore, we asked next whether URI-amplified and
non-URI-amplified ovarian cancer cells display differential
sensitivity toward the mTOR inhibitor rapamycin in a colony
formation assay. Indeed, already low concentrations of rapamy-
cin inhibited colony formation of the non-URI-amplified cell lines
HOSE, TOV-21G, and SKOV-3, whereas the URI-amplified cell
lines OVCAR-3 and FU-OV-1 were significantly less sensitive
to rapamycin (Figure 6A). Immunoblotting confirmed that in the
former set of non-URI-amplified cell lines, S6K1 phosphorylation
was inhibited in a dose-dependent manner, whereas in the latter
set ofURI-amplified cell lines, S6K1 phosphorylation persisted in
the presence of rapamycin (Figure 6A). Importantly, phosphory-
lation of 4EBP1, another known downstream effector of mTOR,
was inhibited to similar extend in all cell lines (Figure 6A), further
supporting the notion that the URI-PP1g axis targets selectively
the S6K1 signaling branch. The importance of maintaining active
S6K1 for efficient colony formation in URI-amplified cells is
illustrated by the fact that OVCAR-3 and FU-OV-1 like non-
URI-amplified cell lines display significantly reduced colony
formation capacity following shRNA-mediated knockdown of
S6K1 (Figure 6B). Immunoblotting confirmed efficient down-
regulation of S6K1 in each of these cell lines under investigation
(Figure 6B). Therefore, similar to what is observed under condi-
tions of serum limitations, URI amplification mediates increased
resistance to rapamycin.
URI Overexpression in Ovarian Cancer Cells
Mediates Resistance to Cisplatin
The 19q12 amplicon was recently identified in a genomewide
screen and was shown to correlate with resistance against
platinum-based chemotherapy in ovarian cancer (Etemadmog-
hadam et al., 2009). In addition, URI amplification correlates
with the failure of ovarian cancer cells to respond to platin-based
chemotherapy (see Figure 1G). In light of its role in suppressing
PP1g-mediated negative feedback, we asked whether overex-
pression of URI contributes to resistance against cisplatin. Clo-
nogenic assays revealed that overexpression of either HA-URI
(wt) or HA-URI(S371A) mutant in otherwise cisplatin-sensitive
TOV-21G cells promoted cisplatin-resistance in a PP1g-depen-
dent manner (Figure 7A). Interestingly, treatment of TOV-21G
cells for 4–7 hr with cisplatin induced both S6K1 and BAD phos-
phorylation (Figure 7B). At 14 hr, phosphorylation of S6K1 and
BAD was diminished again and poly(ADP-ribose) polymerase
(PARP)-cleavage, as an indicator of cell death, was detectable(B) Immunoblot analysis of S6K1 knockdown in TOV-21G and FU-OV-1 cells with
quantification.
(C) TUNEL staining and quantification of TOV-21G and FU-OV-1 cells after S6K1
(D) TUNEL staining and quantification of FU-OV-1 cells with knockdown (KD1) o
(E) PP1g-immunoprecipitation blotted for indicated proteins on cells transfected
(F) Corresponding immunoblot analysis against the proteins and phosphosites in
(G) Correlations of URI, P-S6K1 (T421/S424) (pS6K), and P-BAD S136 on ovarian
pattern exemplified on tumors with weak or strong URI expression. Bars represen
were due to tissue damage (either tissue loss or inadequate tumor tissue).
All error bars in the entire figure represent ± SD of three independent experimen(Figure 7B). TOV-21G cell pools stably expressing HA-URI(wt)
or HA-URI(S371A) enhanced the effect of cisplatin on the
phosphorylation of S6K1 and BAD, consistent with the notion
that URI had entrapped and inhibited PP1g resulting in increased
S6K1 survival signaling. Indeed, when TOV-21G cells were
depleted for S6K1 and treated with cisplatin, we observed
further reduction in cell viability compared to cisplatin treatment
alone (Figure 7C). Similar effects were observed for OVCAR-3
cells (Figure 7C). In FU-OV-1 cells, we did not observe such
a synergism between S6K1 depletion and cisplatin (Figure 7C).
This finding implies that ovarian cancer cells display, in the
context of cisplatin treatment, different degrees of dependen-
cies for S6K1 survival signaling. Depletion of URI sensitized
selectively URI-amplified OVCAR-3 but not the non-URI-ampli-
fied TOV-21G cells to cisplatin (Figure 7D). This is consistent
with the observation that, in URI-amplified OVCAR-3 cells,
S6K1 activity is dependent on URI expression (Figure 5A). As
one would expect, URI depletion did not further reduce cell
viability of cisplatin-treated FU-OV-1 cells (Figure 7C). These
data imply that in ovarian cancer cells URI amplification contrib-
utes to cisplatin resistance, at least in part, by modulating S6K1
signaling.
DISCUSSION
Here we report that a subset of both established ovarian cancer
cell lines and advanced human ovarian cancers are character-
ized by amplification and overexpression of URI, a gene whose
product acts as an inhibitor of PP1g and thus PP1g-mediated
inactivation of S6K1 survival signaling. Only ovarian cancer cell
lines that feature increased URI gene copy number at 19q12
experience a survival defect and decreased S6K1 activity after
deprivation of URI by RNAi, effects that were overridden when
the same cells were also depleted for PP1g. Such cell lines,
when deprived of URI, were also severely compromised for de
novo tumorigenesis in nude mice. Moreover, conditional deple-
tion of URI after tumor establishment also blocked subsequent
tumor growth in vivo. Conversely, in ovarian cancer cell lines
lacking URI amplification, overexpression of URI caused
sustained S6K1 activity and BAD phosphorylation under condi-
tions of growth-factor limitations, enhanced cell proliferation
and tumor growth in vivo. In addition, these otherwise
cisplatin-sensitive ovarian cancer cells converted upon overex-
pression of URI to cisplatin-resistant cells, consistent with the
observed positive correlation between resistance of ovarian
cancer cells to cisplatin and amplification ofURI. Taken together,
these findings strongly support the conclusion thatURI functions
as an ‘‘addicting’’ oncogene that supports uncontrolled celltwo different shRNAs and clonogenic assay of these cells with the respective
knockdown with two different shRNAs. Bars represent 20 mM.
f URI and overexpression of myc-tagged S6K1.
with control and myc-tagged S6K1 overexpression in FU-OV-1 cells.
dicated.
carcinoma TMA (R = correlation coefficient, p value, Kendall beta-tau). Staining
t 20 mm. Differences in number of cases among immunohistochemical markers
ts in triplicate (*p < 0.05 and **p < 0.01, Student’s t test). See also Figure S5.
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Figure 6. URI-Amplified Cells Are More Resistant to mTOR Inhibition by Rapamycin
(A) Clonogenic assays of the primary human HOSE, TOV-21G, SKOV-13, OVCAR-3, and FU-OV-1 cells with the indicated rapamycin concentrations and
corresponding quantification. Corresponding immunoblotting for indicated proteins at various serum concentrations.
(B) Clonogenic assays of the indicated cell lines with S6K1-knockdown mediated by two different short-hairpins and corresponding quantification. Correspond-
ing immunoblotting for knock-down validation.
All error bars in the entire figure represent ± SD of three independent experiments in triplicate.
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URI Functions as an Oncogeneproliferation and contributes to chemotherapy resistance of
certain ovarian cancer cells by disabling a PP1g-mediated nega-
tive feedback pathway that normally acts to restrain S6K1
survival signaling. The fact that URI amplification is observed in
several distinct cancer types implies that abrogation of this
negative feedback pathway may represent a key mechanism
of apoptosis evasion during tumor cell evolution.328 Cancer Cell 19, 317–332, March 15, 2011 ª2011 Elsevier Inc.The biological effect of the 19q12 amplicon has been tradition-
ally linked to CCNE1, the gene encoding then positive cell cycle
regulator cyclin E (Lin et al., 2000; Nakanishi et al., 2000; Schraml
et al., 2003). Congruently, this locus has been found to correlate
with increased cell proliferation and tumor growth. However, an
early report on gastric adenocarcinoma reported that, in some
cases, gene amplification at 19q12 was not associated with
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Figure 7. URI Overexpression in Ovarian Cancer Cells Mediates Resistance to Cisplatin
(A) Clonogenic assay and quantification of TOV21-G cells with vector control and an overexpression of HA-tagged wild-type URI and S371A mutant.
(B) Immunoblotting for proteins and phosphosites as indicated of a time-course experiment at 3.5% serum concentration in TOV-21G cells with vector control
and an overexpression of HA-tagged wild-type URI and S371A mutant.
(C)MTT cell viability assaywith control and knockdown of S6K1 in TOV-21G, OVCAR-3, and FU-OV-1 cells (for corresponding knockdown efficacy, see Figure 5B
and Figure 6B).
(D) MTT cell viability assay with control and knockdown of URI in TOV-21G, OVCAR-3, and FU-OV-1 cells (left panels). Immunoblotting for URI in URI-knockdown
TOV-21G, OVCAR-3, and FU-OV-1 cells (right panels).
All error bars in the entire figure represent ±SD of three independent experiments in triplicate (*p < 0.05 and **p < 0.01, Student’s t test).
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URI Functions as an OncogeneDNA copy number gain at CCNE1, concluding that other genes
within this region may have important functions in tumor devel-
opment (Leung et al., 2006). In this regard, a recent reportsuggested an association of amplification at 19q12 with chemo-
therapy resistance in ovarian cancer (Etemadmoghadam et al.,
2009). Our results functionally link URI overexpression toCancer Cell 19, 317–332, March 15, 2011 ª2011 Elsevier Inc. 329
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URI Functions as an Oncogenesuppression of apoptosis and hence chemotherapy resistance.
The anatomical proximity of CCNE1 and URI at 19q12 may
provide for many carcinomas a unique opportunity of a selective
advantage through coamplification of key genes involved in
promoting cell cycle (CCNE1) and cell survival (URI). This might
also help to explain why 19q12-amplified carcinomas have
such a poor prognosis among ovarian carcinomas. Although
highest URI protein levels were observed in the context of
gene amplification at chromosome 19q12, a substantial amount
of ovarian carcinomas expressed also high levels of URI mRNA
and protein in the absence of gene amplification, indicating
that additional, yet to be elucidated mechanisms may contribute
to URI overexpression and suppression of apoptosis.
At the root of apoptosis, evasion mediated by oncogenic acti-
vation of URI appears to be the previously described inhibitory
interaction of URI with PP1g at mitochondria (Djouder et al.,
2007). According to the proposed model, acute growth factor
and nutrient-dependent activation of S6K1 leads not only to
phosphorylation of BAD at mitochondria but also to that of URI
at Ser-371. The latter event causes disruption of URI-PP1g
complexes releasing PP1g, which in turn, proceeds to dephos-
phorylate and inactivate S6K1 as part of a negative feedback
system dedicated to dampen S6K1 survival signaling. Accord-
ingly, for cancer cells to achieve increased S6K1 survival
signaling output under stress conditions such as growth factor
limitations, one or more aspects of this negative feedback
system must be abrogated by oncogenic events. On the basis
of the results shown here, we propose that URI amplification
and overexpression inactivates the feedback pathway by notori-
ously entrapping PP1g in inactive complexes. In this regard, we
observed no increase in Ser-371 phosphorylation of URI in
ovarian cancer cells featuring URI amplification. Consistent
with this, also much more PP1g was bound to URI in URI-
amplified ovarian cancer cells. This may also help to explain
why URI depletion caused cell death selectively in ovarian
cancer cells with URI gene copy number alterations.
An increasing number of reports indicate a role for S6K1 in cell
survival, at least in part by its ability to sequester BAD frommito-
chondria (Datta et al., 2002; Djouder et al., 2007; Harada et al.,
2001; Nakamura et al., 2008; Strobel et al., 1998). Indeed, we
and others found that damaging agents such as chemothera-
peutics and UV-irradiation promote S6K1 activity as part of an
adaptive survival response (Dhar and Basu, 2008; Hartman
et al., 2010; Huang et al., 2002; Lei et al., 2009; Shi et al.,
1995; Strobel et al., 1998; Wu et al., 2005). In the context of
tumorigenesis, a recently performed synthetic-lethality screen
brought to light that K-ras–transformed cancer cells depend on
S6K1-survival signaling (Scholl et al., 2009). Our data further
highlight the importance of S6K1 in cancer cell survival by linking
its activity, at least in part, to the 19q12 amplicon in ovarian
cancer cells.
S6K1 represents one of several downstream targets of mTOR,
which has emerged as a critical effector in cell signaling path-
ways commonly deregulated in human cancers. This has led to
the prediction that mTOR inhibitors may be useful as anticancer
agents. Indeed, derivatives of one such molecule, rapamycin,
are currently in clinical development. The finding of a disabled
negative feedback in a subset of ovarian cancer cells character-
ized by URI amplification combined with the observation that330 Cancer Cell 19, 317–332, March 15, 2011 ª2011 Elsevier Inc.also fractions of other human cancers feature an amplification
of URI, point to a possible resistance of these cancers to rapa-
mycin or its derivatives. In support of this view, rapamycin was
indeed less efficient in inhibiting S6K1 activity and colony forma-
tion in ovarian cancer cells in which negative feedback inhibition
was disrupted by URI amplification. Of note, in these cancer
cells, rapamycin did inhibit phosphorylation of 4EBP1, another
downstream target of mTOR (Figure 6A). Therefore, it is conceiv-
able to propose that oncogenic activation of URI disrupts cell
signaling downstream of mTOR by affecting selectively the
S6K1 survival signaling branch of this central growth regulatory
pathway.
Taken together, our results add an important molecular mech-
anism of intrinsic apoptosis evasion in cancer and functionally
link the 19q12 amplicon to apoptosis resistance of ovarian
cancer cells and to platinum-based chemotherapy. The fact
that down-regulation of URI selectively affects the viability of
those cells that feature amplification of URI implies that it has
properties of an ‘‘addicting’’ oncogene and provides an opportu-
nity for targeted therapeutic intervention. A small molecule that
specifically disrupts URI-PP1g complexes could dramatically
lower the apoptotic threshold in URI-amplified cancer cells.
Such a drug could prove to be successful for the treatment of
carcinomas with a 19q12 amplicon in combination with conven-
tional chemotherapy or oncogenic kinase inhibitors.
EXPERIMENTAL PROCEDURES
Clonogenic Assays, TUNEL and Cell Proliferation, and MTT
For clonogenic assays, cells of the respective cell line were seeded in 6-well
plates (NUNC) and grown under the indicated conditions. In the case of
TOV-21G and HOSE cells, 5000 cells/well were seeded and cultured for
8 days. SKOV-3 cells were seeded at 3500 cells/well, FU-OV-1 at 7500
cells/well, and OVCAR-3 at 12,000 cells/well, respectively, and were cultured
for 16 days. Plates were fixed and stained using Giemsa’s azur eosin methy-
lene blue (MERCK), diluted 1:1 in 100% methanol. The number of colonies
(defined as cell clusters consisting of at least 50 cells) was quantified by Anal-
ysis software (Olympus Biosystems). For quantification of apoptotic cells and
cellular proliferation, cells were seeded in 96-well plates (Microclear black,
Greiner) and grown for 3 days, fixed with 4% paraformaldehyde for 10 min,
stained with TUNEL (In Situ Cell Death Detection Kit, TMR red, Roche Applied
Science), and counterstained with Phalloidin (Alexa fluor 488, Invitrogen) and
DAPI (SIGMA) according to manufacturer’s protocols. Number of cells and
anaphases detected by DAPI and apoptotic figures detected by TUNEL
were counted in nine 203 fields per well. For cell viability MTT assay, cells
were seeded at high density in a 96-well format (NUNC) and were treated for
24 hr with the indicated concentrations of cisplatin (SIGMA). MTT viability
assay was performed as described elsewhere (Fanning et al., 1990). Details
regarding cell culture and immunoblotting can be found in the Supplemental
Experimental Procedures.
SNP-Array
Genomic DNA was extracted using a DNeasy kit (QIAGEN) from FU-OV-1 and
OVCAR-3 cells and subsequently analyzed for copy variation of nonpolymor-
phic probes by Affymetrix SNP 6.0 arrays according to manufacturer’s
protocol. Absolute signal intensities normalized to corresponding set of
HapMap references were displayed in the Smooth Signal Mode.
Human Tumor Samples
Tumor specimens and clinical data were obtained from two different cohorts,
the Institute of Surgical Pathology and the local cancer registry at the Univer-
sity Hospital Zurich and Basel, with the approval of the institutional review
boards and the local ethics committee of the Kanton Zurich, Switzerland.
Informed consent was obtained from all subjects (reference numbers StV
Cancer Cell
URI Functions as an Oncogene12-2005, 27-2009, 29-2007, and KEK-ZH 2010-0093/0). Details on the charac-
terization of the clinical data and different TMAs can be found in Supplemental
Experimental Procedures.
Immunohistochemistry and FISH
For the detection of P-S6K1 (T421/S424), Ki-67, and P-BAD (S136), slides
were analyzed with the Ventana Benchmark automated staining system (Ven-
tana Medical Systems, Tucson, Arizona) using Ventana reagents for the entire
procedure. For antigen retrieval, slides were heated with cell-conditioning
solution for 1 hr (CC1; Tris-based buffer with slightly alkaline pH) using a stan-
dard protocol. Thereafter, slides were incubated with the primary antibodies at
following concentrations: P-S6K1 (1:100), ki-67 (1:100), and P-BAD (1:100) for
1 hr. Detection was performed using the UView HRP system (Ventana Medical
Systems, Tucson, Arizona). In the case of URI and PP1g, slides were analyzed
with the BondMax staining system (Vision BioSystems, acquired by Leica
Microsystems). For antigen retrieval, slides were heated with cell-conditioning
solution for 30min (H1; Tris-based buffer with slightly alkaline pH). Then, slides
were incubated with the primary antibodies at following concentrations: URI
(1:500) and PP1g 1:100 for 1 hr. Detection was carried out using the Bond
Intense R Detection kit, according to the manufacturer’s recommendations.
Details on the scoring of staining pattern and FISH against URI can be found
in Supplemental Experimental Procedures.
Xenograft Studies
All animal work was performed in accordance with the guidelines of the Insti-
tutional Animal Care and local veterinary office and ethics committee of the
Kanton Zurich, Switzerland (reference number 199/2008) under approved
protocols. To study primary tumorigenesis, TOV-21G cells harvested from
culture were resuspended in PBS at a concentration of 2.5 3 106 cells/ml
and were injected subcutaneously into female athymic nude mice. For
OVCAR-3 cells, the corresponding procedure has been described elsewhere
(Hamilton et al., 1983). We created a regulable Tet-Off OVCAR-3 cell line,
which expresses a microRNA-based hairpin against URI (Open Biosystems
V2HS_23227) after doxycycline withdrawal from the medium, as described
elsewhere (Dickins et al., 2005). More specifically, we used two different
clones, which were validated by western blot and colony formation assays
(Figure S2D). Doxycycline (2 mg/ml) was administered in the drinking water
before and after injection of the cells. It was withdrawn from the drinking water
after tumors had formed. Primary tumor volume was measured every 3 days.
Statistical Analysis
The Kaplan-Meier method was used to estimate survival curves for human
patients and log-rank was used to evaluate statistical differences. Kendall’s
tau-beta was used for correlating ordinal expression variables on TMAs with
each other. A two-sided independent Student’s t test without equal variance
assumption was performed to analyze the results of cell culture experiments.
Wilcoxon rank test was used for evaluating differences within tumor growth of
TOV-21G cells with and without overexpression of HA-tagged URI constructs.
ACCESSION NUMBERS
SNP-array data on FU-OV-1 and OVCAR-3 cells have been deposited in the
Gene Expression Omnibus website with accession code GSE26301.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
ccr.2011.01.019.
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